Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome
NCT ID: NCT03226444
Last Updated: 2020-01-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
204 participants
INTERVENTIONAL
2017-06-30
2019-12-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluate the Efficacy and Safety of LO2A Eye Drops for Symptomatic Improvement of Dry Eye in Patients With Sjögren's Syndrome
NCT03319420
Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome
NCT04819269
Evaluating a New Therapy for Dry Eye in Patients With Sjögren's Syndrome
NCT07277257
A Study Evaluating the Efficacy and Safety of RCI001 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye
NCT07068958
A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
NCT06424444
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
0.005% Lacripep
0.005% Lacripep ophthalmic solution
0.005% Lacripep
One drop (approximately 50 microliters) of 0.005% ophthalmic solution will be administered three times a day (TID) to both eyes for four weeks.
0.01% Lacripep
0.01% Lacripep ophthalmic solution
0.01% Lacripep
One drop (approximately 50 microliters) of 0.01% ophthalmic solution will be administered three times a day (TID) to both eyes for four weeks.
placebo
placebo solution
Placebo
One drop (approximately 50 microliters) of placebo solution will be administered three times a day (TID) to both eyes for four weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
0.005% Lacripep
One drop (approximately 50 microliters) of 0.005% ophthalmic solution will be administered three times a day (TID) to both eyes for four weeks.
0.01% Lacripep
One drop (approximately 50 microliters) of 0.01% ophthalmic solution will be administered three times a day (TID) to both eyes for four weeks.
Placebo
One drop (approximately 50 microliters) of placebo solution will be administered three times a day (TID) to both eyes for four weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Subjects who are age 18 years of age or older at the time of obtaining informed consent.
2. Subjects with a documented prior history or current diagnosis of Primary Sjögren's Syndrome according the American-European Consensus Group Sjögren's Syndrome Criteria (Appendix 4; must meet either 4 out of 6 total criteria OR 3 out of 4 signs). Note: Subjects who are on systemic (oral) therapy for the treatment of Sjögren's Syndrome must be on stable systemic treatment defined as the same treatment for the immediately prior 90 days.
3. Subjects with a history of dry eye-related ocular symptoms, and who have self-reported use of over the counter ocular wetting agents within the last 120 days.
4. Subjects who meet the following criteria at both screening and Visit 2 (Randomization/Baseline) examinations:
1. FCS total score ≥ 4 and \< 15 in the NEI/Industry Workshop scale, (Appendix 6)
2. Symptom Severity score of ≥ 40 using the SANDE questionnaire (Appendix 3)
3. Anesthetized Schirmer test score ≤ 5 mm wetting/5 min
4. LGCS total score ≥ 5 using the NEI/Industry Workshop scale (where 0=no staining) Note: Subjects must meet all 4 criteria and eligible scores for FCS, Anesthetized Schirmer and LGCS must be in at least one eye and it must be in the same eye at the time of the visit.
Exclusion Criteria
1. Subjects with any active infectious ocular condition.
2. Subjects who are monocular or have a BCVA, using corrective lenses if necessary, of +1.0 logMAR or worse as assessed by Early Treatment Diabetic Retinopathy Study (ETDRS).
3. Subjects with ocular inflammatory conditions (e.g., conjunctivitis, keratitis, anterior blepharitis, etc.) not related to dry eye syndrome.
4. Subjects with clinical evidence of cicatricial ocular surface disease, such as cicatricial ocular pemphigoid or Stevens Johnson syndrome.
5. Subjects who cannot suspend the use of any topical eye medications (including topical cyclosporine) other than the investigational product during the run-in and the study treatment phase.
6. Subjects who have used Restasis® (topical ophthalmic cyclosporine) or Xiidra® (topical ophthalmic lifitegrast) within 14 days prior to Visit 1.
7. Subjects who in the study eye have fluorescein corneal staining (FCS) Total Score = 15 or a Score = 3 in the superior region per the NEI/Industry Workshop scale or subjects who have FCS with diffuse confluent staining, filaments or frank epithelial defects.
8. Subjects who have active or have had an outbreak of herpetic keratitis within 365 days of Visit 1 or subjects who are on chronic oral antivirals for ocular herpetic disease.
9. Subjects who cannot suspend the use of and abstain from contact lens use from the Screening Visit (Visit 1) to the end of the study (Visit 5).
10. Subjects who have a history of collagen vascular disease, auto immune disease or rheumatic disease other than Primary Sjögren's Syndrome (e.g., Lupus, Rheumatoid Arthritis, etc.).
11. Subjects who have a history of or current Anterior Membrane Dystrophy.
12. Subjects who have had a corneal transplant or similar corneal surgery (DALK, DSEK, DMEK, etc.).
13. Subjects who have used or anticipate use of amiodarone.
14. Subjects who within 30 days prior to Visit 1 alter the dose or anticipate alterations to the dose of the following: tetracyclines, Omega 3's or 6's.
15. Subjects who within 60 days prior to Visit 1 and for the duration of the study alter the dose or anticipate alterations to the dose of the following: anticholinergics, antidepressants, oral contraceptives, isotretinoin, oral systemic corticosteroids, oral systemic immunosuppressive agents.
16. Subjects who within 30 days prior to Visit 1 and for the duration of the study use topical ocular antihistamines, ocular, inhaled or intranasal corticosteroids, topical or oral mast cell stabilizers, oral antihistamines, topical or nasal vasoconstrictors, topical ocular NSAIDs, topical ocular antibiotics or serum tears.
17. Subjects who in the study eye have had cauterization of the punctum or alterations to (insertion or removal) punctal plug(s) within the past 14 days prior to Visit 1. Note: If a punctal plug in place at Visit 2 (Randomization/Baseline) and it is dislodged, the plug should be replaced as soon as possible.
18. Subjects who, in the study eye, have had corneal refractive surgery (LASIK, PRK, RK).
19. Subjects who in the study eye, have a history of any operative procedure on the ocular surface or eyelids within 365 days prior to Visit 1 or with a history of intraocular surgery within 90 days prior to Visit 1.
20. Subjects who are pregnant or suspected to be pregnant and subjects who are breastfeeding or intend to breastfeed. Female subjects of childbearing potential are required to have a negative urine pregnancy test at screening, and must agree to use an acceptable method of contraception from the time of signing informed consent until the end of study visit. Medically acceptable contraception methods include intrauterine device; barrier methods such as diaphragm, condom, cap or sponge, used with a spermicide; or hormonal contraception.
21. Subjects with any physical or mental impairment that would preclude participation and the ability to give informed consent.
22. Subjects who have participated in a device or Investigational drug study or clinical trial within 30 days of Visit 1. Participation in another during this study is excluded for the duration of this study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
TearSolutions, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marc Odrich, MD
Role: STUDY_DIRECTOR
TearSolutions, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Colorado Department of Ophthalmology
Aurora, Colorado, United States
Corneal Consultants of Colorado
Littleton, Colorado, United States
Bruce A. Segal, MD PA Private Practice
Delray Beach, Florida, United States
University of Alabama Eye Center
Birmingham, Alabama, United States
Doctor My Eyes / Stephen Cohen, OD, PC
Scottsdale, Arizona, United States
Schwartz Laser Eye Center
Scottsdale, Arizona, United States
Milton M. Hom, OD FAAO FACAA (Sc)
Azusa, California, United States
University of California, Berkeley, School of Optometry
Berkeley, California, United States
Orange County Ophthalmology
Garden Grove, California, United States
Lugene Eye Institute
Glendale, California, United States
Martel Eye Medical Group
Rancho Cordova, California, United States
Wolstan & Goldberg Eye Associates
Torrance, California, United States
Bowden Eye & Associates
Jacksonville, Florida, United States
International Eye Associates, PA
Ormond Beach, Florida, United States
Perez Eye Center
Tampa, Florida, United States
Eye Consultants of Atlanta
Atlanta, Georgia, United States
Chicago Cornea Consultants, Ltd.
Hoffman Estates, Illinois, United States
Midwest Cornea Associates, LLC
Indianapolis, Indiana, United States
The Eye Care Institute
Louisville, Kentucky, United States
Clinical Eye Research of Boston
Winchester, Massachusetts, United States
Minnesota Eye Consultants, P.A.
Bloomington, Minnesota, United States
Tauber Eye Center
Kansas City, Missouri, United States
Ophthalmology Associates
St Louis, Missouri, United States
Cornea Consultants of Albany
Slingerlands, New York, United States
Cornerstone Eye Care, PA
High Point, North Carolina, United States
Bergstrom Eye Research
Fargo, North Dakota, United States
Abrams Eye Center
Cleveland, Ohio, United States
Ophthalmic Surgeons & Consultants of Ohio; The Eye Center of Columbus
Columbus, Ohio, United States
University of Pennsylvania Scheie Eye Institute
Philadelphia, Pennsylvania, United States
Black Hills Eye Institute
Rapid City, South Dakota, United States
UTHSC Department of Ophthalmology
Memphis, Tennessee, United States
The Eye Clinic of Texas, an affiliate of Houston Eye Associates
League City, Texas, United States
University of Virginia University Eye Center
Charlottesville, Virginia, United States
Virginia Eye Consultants
Norfolk, Virginia, United States
Vistar Eye Center
Roanoke, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LOS-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.